99- Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, et al. Highly
activated and expanded natural killer cells for multiple myeloma immunotherapy.
Haematologica. 2012;97:1348–56. - Gould SJ, Subramani S. Firefly luciferase as a tool in molecular and cell biology. Anal
Biochem. 1988;175:5–13. - Moriyama EH, Niedre MJ, Jarvi MT, Mocanu JD, Moriyama Y, Subarsky P, et al. The influ-
ence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro.
Photochem Photobiol Sci. 2008;7:675–80. - Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J. Luciferase expression and bioluminescence
does not affect tumor cell growth in vitro or in vivo. Mol Cancer. 2010;9:299. - Troy T, Jekic-McMullen D, Sambucetti L, Rice B. Quantitative comparison of the sensitivity
of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging.
2004;3:9–23. - O'Farrell AC, Shnyder SD, Marston G, Coletta PL, Gill JH. Non-invasive molecular imaging
for preclinical cancer therapeutic development. Br J Pharmacol. 2013;169:719–35. - Dickson PV, Hamner B, Ng CY, Hall MM, Zhou J, Hargrove PW, et al. In vivo biolumines-
cence imaging for early detection and monitoring of disease progression in a murine model of
neuroblastoma. J Pediatr Surg. 2007;42:1172–9. - Jurczok A, Fornara P, Soling A. Bioluminescence imaging to monitor bladder cancer cell adhe-
sion in vivo: a new approach to optimize a syngeneic, orthotopic, murine bladder cancer
model. BJU Int. 2008;101:120–4. - Nogawa M, Yuasa T, Kimura S, Kuroda J, Sato K, Segawa H, et al. Monitoring luciferase- labeled
cancer cell growth and metastasis in different in vivo models. Cancer Lett. 2005;217:243–53. - Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclini-
cal trials. Clin Cancer Res. 2006;12:5288–97. - Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer thera-
peutics. Annu Rev Med. 2006;57:99–118. - Hasegawa S, Furukawa T, Saga T. Molecular MR imaging of cancer gene therapy: ferritin
transgene reporter takes the stage. Magn Reson Med Sci. 2010;9:37–47. - Kassouf W, Brown GA, Shetty A, Hazle JD, Stafford RJ, Rosser CJ, et al. An in vivo orthotopic
canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy
and drug delivery for prostate cancer. Urology. 2007;70:822–5. - Breton E, Goetz C, Kintz J, Accart N, Aubertin G, Grellier B, et al. In vivo preclinical low-field
MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice
model of human glioblastoma. C R Biol. 2010;333:220–5. - Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/
Salmon plus staging system. Eur J Cancer. 2006;42:1539–43. - Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol. 2005;205:194–205.
- Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/
CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary
results. Eur J Nucl Med Mol Imaging. 2006;33:525–31. - Grange C, Geninatti-Crich S, Esposito G, Alberti D, Tei L, Bussolati B, et al. Combined
delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted
doxorubicin- containing liposomes in experimentally induced Kaposi’s sarcoma. Cancer Res.
2010;70:2180–90. - Strijkers GJ, Kluza E, Van Tilborg GA, van der Schaft DW, Griffioen AW, Mulder WJ, et al.
Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor
angiogenesis. Angiogenesis. 2010;13:161–73. - Zaidi H, Prasad R. Advances in multimodality molecular imaging. J Med Phys. 2009;34:122–8.
- Vansteenkiste JF. Imaging in lung cancer: positron emission tomography scan. Eur Respir
J Suppl. 2002;35:49s–60s. - Otsuka H, Morita N, Yamashita K, Nishitani H. FDG-PET/CT for cancer management. J Med
Invest. 2007;54:195–9.
6 MRI & PET for Evaluation of Myeloma in SCID-hu Mice